Welcome to our dedicated page for Coherus SEC filings (Ticker: CHRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Coherus Oncology, Inc. (CHRS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, which Coherus uses to furnish quarterly financial results, report material events and disclose listing-related matters.
Recent Form 8-K filings show that Coherus Oncology reports quarterly earnings and business updates, including net revenue from continuing operations, research and development expenses associated with its immuno-oncology pipeline, and selling, general and administrative costs. These filings also describe trends in LOQTORZI net product revenue and provide context on how development of CHS-114 and casdozokitug contributes to overall spending.
Coherus’ SEC filings additionally document Nasdaq listing status. In a June 30, 2025 Form 8-K, the company reported receiving a deficiency notice related to the minimum bid price requirement. A subsequent Form 8-K dated September 5, 2025, reported that Coherus had regained compliance with Nasdaq Listing Rule 5550(a)(2) and was in full compliance with all continued listing standards of The Nasdaq Global Market.
Through Stock Titan, readers can follow these filings as they are made available on EDGAR, while AI-powered summaries help explain the key points in accessible language. This includes highlighting items such as results of operations, financing arrangements, divestitures, and other events that Coherus Oncology identifies as material to shareholders.
For investors analyzing CHRS, the filings page offers a structured view into the company’s financial condition, capital structure, and regulatory communications, complementing clinical and commercial news about LOQTORZI and the broader immuno-oncology pipeline.
Coherus Oncology, Inc. describes a strategic shift to become a fully integrated commercial-stage oncology company centered on its PD‑1 inhibitor LOQTORZI for nasopharyngeal carcinoma and a focused immuno-oncology pipeline.
LOQTORZI is FDA‑approved in the United States for first‑line metastatic or recurrent locally advanced nasopharyngeal carcinoma in combination with cisplatin and gemcitabine, and as monotherapy after platinum-based chemotherapy. The company estimates up to 2,000 recurrent or metastatic NPC patients in the United States are eligible, representing a $250 million market opportunity.
Coherus highlights mid‑stage clinical candidates casdozokitug (anti‑IL‑27) and tagmokitug (anti‑CCR8), both intended for combination use with LOQTORZI and partners’ agents across liver, head and neck, colorectal and other cancers. It reports multiple collaborations and licenses, including Junshi Biosciences, Apotex, Janssen, Adimab and Vaccinex.
The company notes completion of the divestiture of its UDENYCA biosimilar franchise in April 2025, reinforcing its oncology focus. As of June 30 2025, aggregate market value of common stock held by non‑affiliates was approximately $81.9 million, and shares outstanding were 149,889,902 as of February 28 2026.
Coherus Oncology, Inc. reported 2025 results showing strong product growth alongside continued losses from continuing operations. LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024, helping lift total net revenue from continuing operations to $42.2 million from $26.4 million.
The company reduced secured and convertible debt by about 90% over 2024–2025, from $480 million to $38.8 million, and ended 2025 with $172.1 million in cash, cash equivalents and marketable securities. Research and development spending from continuing operations increased to $108.9 million, reflecting investment in pipeline candidates casdozokitug and tagmokitug, while selling, general and administrative expenses declined to $100.6 million.
Net loss from continuing operations for 2025 narrowed to $183.1 million, or $(1.56) per diluted share, from $215.4 million, or $(1.88) per share, in 2024. Including large gains from discontinued operations, Coherus reported full-year net income of $168.0 million for 2025 compared with $28.5 million in 2024.
Coherus Oncology, Inc. completed an underwritten public offering of its common stock. The company sold 28,600,000 shares at a price to the public of $1.75 per share, with underwriters purchasing at $1.645 per share, generating approximately $47.0 million in net proceeds before expenses.
The underwriters also received a 30-day option to buy up to an additional 4,290,000 shares to cover any over-allotments. Coherus, its directors, executive officers and certain affiliated stockholders agreed to a 60-day lock-up on additional common stock sales, subject to specified exceptions.
Coherus Oncology, Inc. is conducting a primary offering of 28,600,000 shares of common stock at $1.75 per share, with expected net proceeds of about $46.5 million, plus a 30‑day option for underwriters to buy up to 4,290,000 additional shares.
The company plans to use the funds to support commercialization of LOQTORZI, advance clinical development of its oncology pipeline, and for working capital and general corporate purposes. Preliminary 2025 results show estimated net revenue of $42.2 million, up from $26.4 million in 2024, driven largely by $40.8 million of LOQTORZI sales.
Cash, cash equivalents and marketable securities are estimated at $172.1 million as of December 31, 2025, and Coherus expects this liquidity to fund operations through the end of 2026, while still recording a loss from continuing operations for the fourth quarter of 2025.
Coherus Oncology is launching a public offering of common stock from its existing shelf registration. The company plans to use proceeds to support commercialization of LOQTORZI, advance clinical development of its oncology pipeline, and for working capital and general corporate purposes.
Preliminary unaudited results for 2025 show net revenue from continuing operations of about $12.7 million for Q4 (vs. $7.7 million a year earlier) and $42.2 million for the full year (vs. $26.4 million), with LOQTORZI contributing most of these amounts. Cash, cash equivalents and marketable securities were approximately $172.1 million as of December 31, 2025, which the company expects will fund operations through the end of 2026.
Coherus describes positive clinical data for LOQTORZI in nasopharyngeal cancer, including a Phase 3 trial showing median overall survival of 64.8 months with LOQTORZI plus chemotherapy versus 33.7 months with chemotherapy alone and an observed 38% reduction in risk of death. Additional Phase 2 data for casdozokitug in liver cancer showed an overall response rate of 38% and complete response rate of 17% in combination therapy, with no new safety signals reported.
Coherus Oncology, Inc. received a Schedule 13G reporting that the Timothy G. Youngquist 2020 Irrevocable Trust beneficially owns 7,850,800 shares of its common stock. This represents 6.49% of the outstanding common shares, based on 120,871,013 shares outstanding as of October 31, 2025.
The trust has sole power to vote and dispose of these 7,850,800 shares. The position includes 560,000 shares underlying call options that are counted as beneficially owned because they are exercisable within 60 days. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Coherus.
Coherus Oncology, Inc. entered into a clinical supply agreement with Janssen Research & Development, LLC to support a Phase 1b study in metastatic castration-resistant prostate cancer. The trial will evaluate Coherus’ investigational anti-CCR8 cytolytic monoclonal antibody tagmokitug (CHS-114) in combination with Janssen’s T-cell engaging bispecific antibody pasritamig.
Under the agreement, Janssen will supply pasritamig, while Coherus will act as sponsor of the Phase 1b clinical trial in patients with metastatic castration-resistant prostate cancer. Each company keeps all commercial rights to its own compound, whether used alone or in combination therapies.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 10,028,893 shares of Coherus Oncology Inc common stock, representing 8.29% of the class. Vanguard reports no sole voting or dispositive power, with 815,663 shares subject to shared voting power and 10,028,893 shares subject to shared dispositive power.
Vanguard explains that an internal realignment on January 12, 2026 means certain subsidiaries or business divisions are expected to report holdings separately on a disaggregated basis, while pursuing the same investment strategies as before. The holdings include securities in the form of rights, and Vanguard states its clients have the right to receive dividends or sale proceeds, with no single other person’s interest exceeding 5%. Vanguard certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Coherus.
Coherus Oncology President & CEO Dennis M. Lanfear reported new equity awards. On January 23, 2026, he received 375,000 restricted stock units of Coherus Oncology common stock at a price of $0. Each RSU converts into one share, with 50% scheduled to vest on May 20, 2027 and 50% on March 20, 2029, subject to his continued service.
He was also granted a stock option for 750,000 shares of common stock at an exercise price of $2.06 per share, expiring January 23, 2036. The option vests as to one-fourth of the shares on the one-year anniversary of January 23, 2026, and the remainder in equal monthly installments thereafter, contingent on continued service. Following these grants, he holds 1,048,235 shares directly, plus indirect holdings of 432,684 shares through a revocable trust and 86,965 shares through an LLC.
Coherus Oncology, Inc.’s Chief Financial Officer, Bryan J. McMichael, reported new equity awards. On January 22, 2026, he received 112,500 restricted stock units of common stock at $0 per share, bringing his directly held common stock to 133,736 shares. These RSUs vest in two equal parts, with 50% vesting on May 20, 2027 and 50% on March 20, 2029, subject to continued service. He was also granted a stock option for 225,000 shares of common stock at an exercise price of $1.59 per share, all held directly. The option vests 25% on the one-year anniversary of January 22, 2026, and the remainder in equal monthly installments over the following three years.